Teva Pharmaceutical Industries Limited (TEVA)
TEVA moved a median of -0.06% 30 minutes after news, and -0.06% by the close. How TEVA actually reacts to news — the realized, point-in-time move the market made, measured across 692 labeled events over the last three years with zero look-ahead.
TEVA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.04% | 46% | 684 |
| 30-min | -0.06% | 49% | 684 |
| 60-min | -0.06% | 47% | 684 |
| to close | -0.06% | 50% | 681 |
| Middle 50% of TEVA reactions | -0.70% to +0.70% |
|---|---|
| Median reaction (30-min) | -0.06% |
| Measured reactions | 692 |
Half of all Teva Pharmaceutical Industries Limited news events land between -0.70% and +0.70% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How TEVA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 34 | +0.70% | 65% | +0.64% |
| Analyst downgrades | 12 | +0.43% | 67% | -0.05% |
| Coverage initiations | 19 | -0.49% | 26% | +0.04% |
| Rating reiterations | 50 | +0.01% | 50% | +0.07% |
| Price-target raises | 38 | +0.02% | 53% | +0.09% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how TEVA ranks against every other measured name →
That’s how TEVA usually reacts — get an email when it moves on news →Email me when TEVA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TEVA's baseline. Nothing else.
Recent TEVA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Teva to Host R&D Day on Wednesday, November 11 in New York City | Press release | GlobeNewswire | +0.41% | +0.05% | |
| Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates | Press release | Business Wire | -0.32% | -0.48% | |
| TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness | Press release | GlobeNewswire | -0.32% | -0.48% | |
| Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab) | Press release | GlobeNewswire | +0.63% | +2.34% | |
| Teva Releases Q3 2026 Aide Memoire | Press release | GlobeNewswire | +0.31% | +3.82% | |
| Form 8-K TEVA PHARMACEUTICAL INDU For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | +0.18% | -1.76% | |
| Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults | Press release | GlobeNewswire | -0.96% | +2.48% | |
| Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs | Press release | GlobeNewswire | -0.96% | +2.48% | |
| Form 8-K TEVA PHARMACEUTICAL INDU For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | +0.69% | +0.59% | |
| Form 8-A12B/A TEVA PHARMACEUTICAL INDU | SEC filing · Form 8-A12B | SEC EDGAR | +0.18% | +1.55% | |
| Form 8-K TEVA PHARMACEUTICAL INDU For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | +0.18% | +1.55% | |
| Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy | Press release | GlobeNewswire | -0.88% | +2.81% | |
| Form 8-K TEVA PHARMACEUTICAL INDU For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | -0.88% | +2.81% | |
| Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes | Press release | GlobeNewswire | +0.01% | -0.06% | |
| Teva Announces Launch of Offering of Senior Notes | Press release | GlobeNewswire | -0.22% | +2.71% | |
| S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline | Press release | GlobeNewswire | +0.41% | -0.84% | |
| Form 8-K TEVA PHARMACEUTICAL INDU For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | -0.47% | -0.11% | |
| Form 8-K TEVA PHARMACEUTICAL INDU For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | -0.47% | -0.11% | |
| Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S. | Press release | GlobeNewswire | -0.71% | -0.90% | |
| Form 10-Q TEVA PHARMACEUTICAL INDU For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.25% | +3.33% | |
| Form 8-K TEVA PHARMACEUTICAL INDU For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +4.51% | +2.75% | |
| Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook | Press release | Business Wire | +4.51% | +2.75% | |
| UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook | Press release | Business Wire | +4.51% | +2.75% | |
| Teva and Samsung Bioepis Enter Commercialization Agreement for OPUVIZ®, a Biosimilar Referencing Eylea® (aflibercept), in Canada | Press release | Canada Newswire | +0.73% | +0.64% | |
| Teva to Present at the Goldman Sachs Global Healthcare Conference | Press release | GlobeNewswire | -2.93% | -3.13% | |
| Form 8-K TEVA PHARMACEUTICAL INDU For: May 28 | SEC filing · Form 8-K | SEC EDGAR | -0.04% | +1.61% | |
| Medincell: The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults | Press release | Business Wire | +0.22% | +0.12% | |
| The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults | Press release | GlobeNewswire | -0.04% | +0.80% | |
| Form 10-Q TEVA PHARMACEUTICAL INDU For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.14% | -2.31% | |
| Form 8-K TEVA PHARMACEUTICAL INDU For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | +2.43% | +4.06% | |
| Medincell - UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year-on-Year | Press release | Business Wire | +2.43% | +4.06% | |
| Form ARS TEVA PHARMACEUTICAL INDU For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.44% | -0.82% | |
| Form DEF 14A TEVA PHARMACEUTICAL INDU For: May 28 | SEC filing · Form DEF | SEC EDGAR | +0.44% | -0.82% | |
| Form DEFA14A TEVA PHARMACEUTICAL INDU | SEC filing · Form DEFA14A | SEC EDGAR | +0.44% | -0.82% | |
| Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug | Press release | GlobeNewswire | -2.30% | -1.02% | |
| Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults | Press release | Business Wire | +0.06% | +0.18% | |
| Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine | Press release | Canada Newswire | -0.35% | -3.29% | |
| Form 10-K TEVA PHARMACEUTICAL INDU For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.93% | +1.71% | |
| Teva Canada Announces Strategic Partnership with Novartis Canada to Relaunch Mayzent® for Multiple Sclerosis Patients in Canada | Press release | Canada Newswire | +0.35% | +2.96% | |
| Form 8-K TEVA PHARMACEUTICAL INDU For: Jan 28 | SEC filing · Form 8-K | SEC EDGAR | +0.41% | +5.87% | |
| Form 8-K TEVA PHARMACEUTICAL INDU For: Jan 11 | SEC filing · Form 8-K | SEC EDGAR | -0.85% | -1.65% | |
| Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo | Press release | GlobeNewswire | -0.85% | -1.65% | |
| Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +2.10% | +1.52% | |
| S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive | Press release | GlobeNewswire | -0.34% | -0.78% | |
| Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® | Press release | GlobeNewswire | +0.07% | +0.83% | |
| Form 8-K TEVA PHARMACEUTICAL INDU For: Dec 10 | SEC filing · Form 8-K | SEC EDGAR | -0.57% | -0.70% | |
| Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December | Press release | GlobeNewswire | +0.61% | +1.10% | |
| Teva Canada Welcomes RAMQ Reimbursement Update Supporting Access to ADHD Treatments | Press release | Canada Newswire | +1.22% | +1.45% | |
| Form 10-Q TEVA PHARMACEUTICAL INDU For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.22% | +1.45% | |
| Form 8-K TEVA PHARMACEUTICAL INDU For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | +2.18% | +6.31% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TEVA section they belong to.
Where else TEVA is measured.
TEVA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ALDER BIOPHARMACEUTICALS INC (ALDR) | 693 | -0.21% | 45% |
| DIGIRAD (DRAD) | 692 | 0.00% | 39% |
| Tyme Technologies, Inc. (TYME) | 691 | -0.28% | 41% |
| Marinus Pharmaceuticals, Inc. (MRNS) | 687 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Teva Pharmaceutical Industries Limited's median reaction calculated?
Every labeled TEVA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 692 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of TEVA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TEVA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.